BMS looks to new products not acquisitions to drive Japanese growth
This article was originally published in Scrip
Bristol-Myers Squibb sees strong growth potential in Japan, a market where its sales have suffered in recent years, and is hoping that the launch of several key new products there over the next four years will take it into the local pharma top 20.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.